Diagnostics/radiopharma sales decline at Schering AG:
This article was originally published in Clinica
Declines in sales of X-ray contrast media and radiopharmaceuticals led to a 3% fall in net sales at Schering AG's diagnostics and radiopharmaceuticals business in 2002. Total divisional revenues of E1,406m ($1,525m) included E327m from MRI contrast agents (+2%) and E264m from contrast agent application technologies (+9%), but X-ray contrast media fell by 9% to E654m and there was a 4% decrease in radiopharmaceutical sales to E146m. The company was hit by negative price pressures and exchange rate effects.